Microbix Biosystems Inc.
Microbix Biosystems Inc. (MBX.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mbx.to · pe ratio · data through Sep 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Microbix Biosystems Inc. (MBX.TO) measures how much investors pay for each dollar of the company's trailing earnings. MBX.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.27 by its TTM earnings per share of -$0.04.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-09-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 8 fiscal years · Front-end computedMinQ1 · 25%47.9x
MedianQ3 · 75%7249.6x
Max
At N/A, MBX.TO's current P/E is lower than in 0% of its annual fiscal year readings over the past 8 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Microbix Biosystems Inc.You MBX.TO | $37M | N/A | — | -$0.04 |
 DIAGNOS Inc. ADK.V | $22M | N/A | — | -$0.05 |
 BriaCell Therapeutics Corp. BCT.TO | $8M | N/A | — | -$62.95 |
 BioMark Diagnostics Inc. BUX.CN | $59M | N/A | — | -$0.02 |
 Charlotte's Web Holdings, Inc. CWEB.TO | $92M | N/A | — | -$0.19 |
 Rapid Dose Therapeutics Corp. DOSE.CN | $12M | N/A | — | -$0.04 |
 Defence Therapeutics Inc. DTC.CN | $29M | N/A | — | -$0.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-09-30Latest FY2025 | — | $-0.02 | — | |
2024-09-30 FY2024 | 13.01x | $0.03 | — | |
2023-09-30 FY2023 | — | $-0.00 | — | |
2022-09-30 FY2022 | 38.60x | $0.01 | -13.0% | |
2021-09-30 FY2021 | 44.38x | $0.01 | — | |
2020-09-30 FY2020 | — | $-0.06 | — | |
2019-09-30 FY2019 | 729.16x | $0.00 | — | |
2018-09-30 FY2018 | — | $-0.09 | — | |
2017-09-30 FY2017 | — | $-0.04 | — | |
2016-09-30 FY2016 | 27.15x | $0.01 | -47.1% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Microbix Biosystems Inc. (MBX.TO) measures how much investors pay for each dollar of the company's trailing earnings. MBX.TO's current PE ratio of N/A is calculated by dividing its stock price of $0.27 by its TTM earnings per share of -$0.04.
Frequently asked questions
MBX.TO pe ratio · 6 questionsMBX.TO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.27 and TTM EPS of -$0.04. Data sourced from Financial Modeling Prep via MBX.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Microbix Biosystems Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09